⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486380 | 0.79 | SIGMAR1 (0.42) | — | |
| SCHEMBL8466136 | 0.79 | SIGMAR1 (0.38) | — | |
| SCHEMBL8469341 | 0.67 | SIGMAR1 (0.38) | — | |
| SCHEMBL7486260 | 0.67 | SIGMAR1 (0.42) | — | |
| SCHEMBL30454517 | 0.67 | SIGMAR1 (0.38) | — | |
| SCHEMBL4624876 | 0.67 | — | — | |
| SCHEMBL147460 | 0.65 | — | — | |
| SCHEMBL16298139 | 0.65 | SIGMAR1 (0.50) | — | |
| SCHEMBL1950016 | 0.64 | SIGMAR1 (0.43) | — | |
| SCHEMBL22123483 | 0.63 | ROCK2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2024-02-29 | — | — | US | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| CN-112105359-B | Pyrrolo [2,3-b ] pyrazine compounds as cccDNA inhibitors for the treatment of Hepatitis B Virus (HBV) infection | 豪夫迈·罗氏有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230322743-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | MIHKAL GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230287413-A1 | TARGETED DELIVERY OF AN INHIBITOR OF MIR-21 TO MACROPHAGES FOR THE TREATMENT OF PULMONARY FIBROSIS | Technische Universität München (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286975-A1 | IMPROVED METHOD FOR THE PRODUCTION OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND NOVEL DERIVATIVES THEREOF | MIHKAL GMBH (CH) | 2023-09-14 | — | — | US | disclosed |
| US-20230248723-A1 | PYRROLO[2,3-B]PYRAZINE COMPOUNDS AS CCCDNA INHIBITORS FOR THE TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION | HOFFMANN-LA ROCHE INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230241226-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF CARRIER PROTEINS AND USES THEREOF | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2023-08-03 | — | — | US | disclosed |
| EP-4217353-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | Ermium Therapeutics (FR) | 2023-08-02 | — | — | EP | disclosed |
| EP-3374360-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | Mavalon Therapeutics Limited (GB) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017081483-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | MAVALON THERAPEUTICS LIMITED (GB) | 2017-05-18 | — | — | WO | disclosed |
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| EP-1065206-B1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1065204-B1 | Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors | PFIZER (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6303628-B1 | FOR THE TREATMENT OF A MEDICAL CONDITION IN WHICH PROSTAGLANDINS ARE IMPLICATED AS PATHOGENS IN MAMMALS | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| EP-1065204-A1 | Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors | PFIZER INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1065206-A1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2001-01-03 | — | — | EP | disclosed |